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Abstract
HIV/HCV co-infected naı¨ve patients (four females and six
males) were evaluated for their response to the following
treatment schedule: [(AZT 300 mg + 3TC 300 mg twice
daily) + (fosamprenavir 700 mg twice daily) + (RTV
100 mg)]. CD3+/CD4+ T cells, interferon-c (INF-c) and
interleukin-4 (IL-4) HCV-speciﬁc response, viral loads and
transaminase levels were evaluated at time 0, and after 1, 3
and 6 months of therapy (T0, T1, T3, and T6 respectively).
HIV-RNA, HCV-RNA and transaminases decreased at T1
and T3 compared with T0 (Mann–Whitney p <0.001,
p <0.01 and p <0.01, respectively). At all time points, CD4+
and HCV-speciﬁc INF-c responses were higher (p <0.001;
p <0.001), and IL-4 lower (p <0.01) after treatment. At T6,
HCV-RNA was only negative in four out of ten patients
whereas all had normal transaminase levels. These ﬁndings
indicate that HAART treatment including fosamprenavir is
able to activate a Th1 network in HIV/HCV co-infected
patients. Moreover, these results, to be conﬁrmed by larger
cohort follow-up studies, suggest that this protease inhibitor
could have potential implications for the treatment of
chronic hepatitis C in HIV-positive patients.
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It is known that HIV/HCV-coinfected patients have a faster
hepatic disease progression with early onset of cirrhosis and
end-stage liver disease [1,2], although discordant data have
been published about HCV inﬂuence on HIV disease progres-
sion [3]. HCV antiviral treatment, nonetheless, represents an
important strategy in the treatment of these patients. Indeed,
chronic hepatitis C treatment should be initiated if the CD4
cell count is >350 cells/L, without the need to begin antiret-
roviral therapy. On the other hand, an antiretroviral treat-
ment (ART) should be commenced in patients showing a
lower CD4+ cell count (<200 cells/L) before embarking on
anti-HCV therapy with interferon and ribavirin [4]. The treat-
ment choice in this latter subset of patients is represented by
highly active antiretroviral therapy (HAART) with particular
attention to possible inﬂuences on liver function. Fosampre-
navir (FA), an oral prodrug of amprenavir, has been included
in the HAART schedule and has been shown to have an
improved bioavailability with a reduced daily pill load for HIV
patients [5]. We evaluated the response to treatment of ten
naı¨ve HIV/HCV-coinfected patients (four female and six
male), from October 2006 to June 2008, undergoing the
following HAART schedule: [(AZT 300 mg + 3TC 300 mg
twice daily) + (fosamprenavir 700 mg twice daily) + (RTV
100 mg)]. Patients had at least a 1-year history of histologi-
cally proven, persistent HCV infection and were either inter-
feron and ribavirin naı¨ve or had been previously treated (at
least 18 months before enrolment). After obtaining written
informed consent, we evaluated immunological, biochemical
and virological parameters at the following time points: Time
0 (T0), after 1 month (T1), 3 months (T3) and 6 months
(T6). HCV-speciﬁc immune response [interferon-c (IFN-c)
and interleuking-4 (IL-4)] was evaluated by ELISpot assay at
T0, T1, T3 and T6 on peripheral blood mononuclear cells
(PBMCs). Cytokine production was assessed after stimulation
with 2 lg/mL of pooled HCV core peptides (35–48—
YLLPRRGPRL; 132–40—DLMGYIPLV—DLMGYIPAV; 41–49
GPRLGVRAT) (Proimmune, Oxford, UK) on 40-mL blood
samples (taken on two different days) with at least 150 000
cells per well; all experiments were carried out in triplicate
and were expressed as spot forming colonies (SFCs). Serum
level transaminases were assayed in our centralized labora-
tory and ﬂow cytometry was used to enumerate lymphocytes
according to protocols previously described [6]. Plasma HCV
and HIV viral loads were measured using the Cobas Amplicor
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Monitor assay with a detection limit of 50 copies/mL for HIV
and 60 IU/mL for HCV (Roche Diagnostics, West Sussex,
UK). All patients were HBsAg negative and did not show
any other acute infection (IgM-HAV; IgM-EBV; IgM-CMV;
IgM-HSV) or autoimmune illness (negative ANA, ASMA and
anti-LKM). Results were expressed as mean and standard
deviation (SD); however, given the small number of subjects,
the nonparametric Mann–Whitney U-test was used. All
hypothesis tests were two-tailed and statistical signiﬁcance
was assessed at p 0.05 using GraphPad Prism 4.0 (GraphPad
Software, Inc., La Jolla, CA, USA).
HIV-RNA was found to be statistically signiﬁcantly
decreased at T1 and was negative at T3, whereas CD4+
T cells increased within the ﬁrst month and were stable by
T3 (Mann–Whitney test p <0.001) (Table 1). HCV viral load
showed a statistically signiﬁcant decrease at T1 compared
with T0 (Mann–Whitney p <0.01) and was negative at T3
(Table 1). Serum transaminase levels were found to be under
the normal limit value at T1 and T3 (Table 1). HCV-speciﬁc
IFN-c SFCs were higher at T1 and T3 than T0, whereas IL-4
SFCs were lower (Mann–Whitney U-test p <0.001 and <0.01
respectively) (Table 1). At the 6 months follow-up, patients
scored negative for HIV viral load, with a stable mean level of
CD4+ (412 ± 32 cells/mm3). On the other hand, six out of
ten patients scored positive for HCV-RNA, with a low titre
(HCV-RNA 75 ± 12 · 103) although serum transaminase lev-
els were under the normal limit value (ALT 32 ± 4 IU/mL;
AST 24 ± 4 IU/mL N.V. <40 IU/mL). A stable and strong
IFN-c HCV-speciﬁc immune response was also conﬁrmed at
T6 (131 ± 12 SFCs) in all patients, whereas IL-4 was stably
lower than T0 (55 ± 7 SFCs). Subjects still positive for HCV-
RNA were enrolled for HCV antiviral treatment.
The efﬁcacy of the HAART schedule including fosampre-
navir against HIV was conﬁrmed in our ten naı¨ve patients
and the treatment was also found to have an impact on
HCV, leading to a statistically signiﬁcant decrease in viral
load and inducing a HCV-speciﬁc pro-inﬂammatory network
shift within 3 months. Indeed, it has been reported that
HAART treatment inﬂuences T cell function recovery, possi-
bly having direct immunomodulatory activity, independent of
their speciﬁc antiretroviral effects, explaining the disconnec-
tion between CD4+ cell counts and viral load in some
treated patients who develop resistant viral mutants [7].
Moreover, spontaneous HCV-RNA clearance during HAART
treatment has also been described [8]. The mechanisms
related to our ﬁndings still remain to be clariﬁed but we
could speculate that the IFN-c immune network shift, proba-
bly related to the immunoreconstitution, might have a role
in this viral clearance as has already been suggested [9].
However, it is of note that this viral clearance seems to per-
sist only in about 40% of treated patients at the sixth month
follow-up in spite of the Th1 network boost and normal
transaminase serum levels observed in all patients. These
features could suggest possible HCV viral escape, eluding the
immune response, and that speciﬁc HCV antiviral treatment
is necessary to achieve sustained HCV clearance. In conclu-
sion, despite the small group, this is the ﬁrst report, to our
knowledge, of a signiﬁcant drop in HCV viral load, with a
Th1 boost and transaminase reduction, during HAART treat-
ment including fosamprenavir. In the light of recent reports
addressing the important role of a rapid virological response
(RVR) in coinfected patients [10] and based on our prelimin-
ary results, we would propose that the use of fosamprenavir
in an HAART schedule, may, through a yet undetermined
immunological and virological pathway, have an impact on
HCV infection in coinfected patients. However, a pegylated
interferon plus ribavirin therapy should be started to achieve
a stable virological response. Future large cohort follow-up
studies should be undertaken to conﬁrm these data and to
gain a better understanding of fosamprenavir activity on the
immune system during HIV/HCV coinfection, as well as
determining the possible therapeutic implications in this
subset of patients.
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TABLE 1. Data were evaluated at Time 0, after 1 month
(T1) and 3 months (T3)
Patient
parameters Time 0 Time 1 Time 3 p
CD3+/CD4+ 186 ± 23 414 ± 63 486 ± 48 <0.001
ALT level (IU/L < 40) 121 ± 44 22 ± 9 30 ± 4 <0.01
AST level (IU/L < 40) 93 ± 31 25 ± 8 28 ± 6 <0.01
HCV-RNA
(IU/mL mean ± SD)
596 ± 236 · 103 13 ± 30 · 103 Negative <0.01
HIV-RNA
(IU/mL mean ± SD)
90 ± 19 · 103 209 ± 42 Negative <0.001
ELISpot assaya
IFN-c 69 ± 13 112 ± 14 122 ± 8 <0.001
IL-4 88 ± 19 48 ± 16 55 ± 16 <0.01
aELISpot assay, expressed as spot forming colonies (SFCs); CD4+ expressed as
cells per cubic millimetre. Data expressed as mean plus standard deviation.
Statistical analysis to assess differences was performed using the Mann–Whitney
U-test.
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Abstract
Between 2005 and 2006, clinical specimens were collected from
31 infants with suspected congenital rubella syndrome (CRS)
who presented at six hospitals in Khartoum, Sudan. Eleven
(35.5%) were laboratory conﬁrmed as CRS cases by testing for
anti-rubella IgM, IgG and viral genome. For the ﬁrst time in
Sudan, the rubella virus genome was directly detected in clinical
specimens of six CRS cases and two viruses were isolated in cell
culture. Phylogenetic analysis suggested that three genotypes of
rubella virus (RV; 1E, 2B and 1G) were co-circulating in Sudan.
The study introduced the methodology for CRS conﬁrmation
and surveillance in Sudan and provides preliminary data.
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Surveillance for measles/rubella is conducted in Sudan, but
rubella vaccination is not included in the national immuniza-
tion programme. Rubella infection was found to be the most
frequent cause of non-measles rash in Khartoum [1]. In
1996, a sero-epidemiological study in Khartoum revealed
that 20.5% of the pregnant women were susceptible to
rubella [2]. However, no surveillance data for the congenital
rubella syndrome (CRS) are available in Sudan. This study
was conducted to provide information on the CRS burden
and characteristics of its causative agent, which may contrib-
ute to the establishment of CRS control strategies in Sudan.
Between June 2005 and May 2006, 31 infants under 1 year
of age who presented at six hospitals in Khartoum with sus-
pected CRS [3] were investigated, and 62 specimens includ-
ing 27 throat swabs (TS), ﬁve nasal swabs (NS), six oral
ﬂuids (OF) and 24 sera were collected. TS and NS were
placed in 2 mL of medium [4] and kept in liquid nitrogen.
OF were collected and extracted as previously described [5]
and kept at )20C, as were the sera, prior to testing [6].
Data on the clinical ﬁndings in the infants and the medical
history of the mothers were recorded (Table 1).
The study protocol was reviewed and approved by the
Ethical Review Committee, Federal Ministry of Health, Sudan.
Parents of infants meeting the CRS case deﬁnition were
informed about the study and consent was obtained before
enrolment.
Sera and OF were tested using a commercial ELISA
for rubella IgM (Microimmune Limited, Brentford, UK), and
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